Molecular structure of Lovastatin, CAS Number: 75330-75-5
Lovastatin (CAS 75330-75-5)
See product citations (12)
Alternate Names:
Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
Application:
Lovastatin is a hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
CAS Number:
75330-75-5
Purity:
≥97%
Molecular Weight:
404.54
Molecular Formula:
C24H36O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.
Lovastatin (CAS 75330-75-5) References
- Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. | Kim, WS., et al. 2001. Invest New Drugs. 19: 81-3. PMID: 11291836
- Cell cycle-specific effects of lovastatin. | Jakóbisiak, M., et al. 1991. Proc Natl Acad Sci U S A. 88: 3628-32. PMID: 1673788
- Inhibition of growth factor signaling pathways by lovastatin. | Vincent, TS., et al. 1991. Biochem Biophys Res Commun. 180: 1284-9. PMID: 1953779
- Lovastatin blocks N-ras oncogene-induced neuronal differentiation. | Mendola, CE. and Backer, JM. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
- All ras proteins are polyisoprenylated but only some are palmitoylated. | Hancock, JF., et al. 1989. Cell. 57: 1167-77. PMID: 2661017
- Discovery, biochemistry and biology of lovastatin. | Alberts, AW. 1988. Am J Cardiol. 62: 10J-15J. PMID: 3055919
- Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing Aβ accumulation. | Xu, Y., et al. 2021. Neurochem Int. 148: 105078. PMID: 34048842
- An overview on the biological activity and anti-cancer mechanism of lovastatin. | Xie, L., et al. 2021. Cell Signal. 87: 110122. PMID: 34438015
- Lovastatin production by an oleaginous fungus, Aspergillus terreus KPR12 using sago processing wastewater (SWW). | Srinivasan, N., et al. 2022. Microb Cell Fact. 21: 22. PMID: 35164756
- Lovastatin production by Aspergillus terreus in membrane gradostat bioreactor with two-stage feeding strategy. | Kargar, S., et al. 2022. Prep Biochem Biotechnol. 1-8. PMID: 35594264
- Neuroprotective effects of lovastatin against traumatic spinal cord injury in rats. | Mirzaie, J., et al. 2022. J Chem Neuroanat. 125: 102148. PMID: 36031087
- Dose- and time-dependent hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats. | Bobek, P., et al. 1998. Nutrition. 14: 282-6. PMID: 9583372
- Lovastatin induces apoptosis in malignant mesothelioma cells. | Rubins, JB., et al. 1998. Am J Respir Crit Care Med. 157: 1616-22. PMID: 9603146
Inhibitor of:
2410076I21Rik, 2410131K14Rik, ABCA, ABCD1, ABCG4, ABCG5, ABHD3, ABR, ACSVL3, ACY1L2, AMAC1L2, Angptl2, Angptl7, ANGRP, APO, apoA-II, apoAL, apoC1, apoE, apoF, APOL (Apolipoprotein L), apoL-VI, APOP1, AQP7, ARHGAP10, ARHGAP11B, ARHGAP12, ARHGAP19, ARHGEF33, ARL16, AS250, BBS9, C18orf45, C19orf12, C8orf80, caveolin-1, caveolin-2, CCDC132, CD1D, Cdc11, Ces1a, claudin-15, CLEC-18C, CLEC-2F, CLEC-2G, Cntnap5c, COASY, CYB5R1, CYP4Z1, Cytokeratin 5, DDHD2, DHCR7, DHS, DNA pol δ 4, dolichol kinase, DSCAML1, DSCR 5, E030010A14Rik, EBPBP β, EBPL, EG432798, EG434008, EG666803, EHHADH, FA2H, FADS6, FGD1, FND3C2, GBP8, GFAP, GGPL-I, GGTase-Iα, GLIPR1L1, Gm239, Gm266, Gm438, GML, GNPAT, GPR87, GRAMD1A, GRAMD1B, GROβ, GTPBP6, HACL1, HADHSC, HAS2, HMG-3, HMG-4, HMGCL, HMGCLL1, HMGCR, HSV-1 gD, ICMT, IDI2, ILBP, INSIG-1, Intectin, Integrin α7, Integrin β3, Integrin X, ITBA1, ITFG3, Kal1, KAO, KRIT1, L-Selectin, LAL, Lamin A/C, Lamin C, Laminin γ-1, LAMP-5, Langerin, LAP2, LARG, LDLR, LDLRAD3, LET-60 RAS, Lfc, LIMP I, LIMP III, LIP1, LIPH, Lipin-2, LOC345643, LOC643008, LPAAT-δ, LPD lipase, LSR, M6A, MAC30, Malcavernin, MANSC4, MARCH (membrane associated ring-CH-type finger), MCCA, MDHC, Mdr-2, megalin, MENTHO, mHMGCS, MK, MLYCD, MOB2, MOD5, Moesin, Multimerin-2, MVD, MVK, MYADML2, N-myristoyltransferase 1, N-myristoyltransferase 2, Nir2, Nir3, NOXA1, Olfr508, Olfr606, Olfr729, Olfr73, Olr222, Olr540, OR2D3, ORP-7_Osbpl7, Otoraplin, PANK4, Paralemmin 3, PCYOX1L, PDI1 ER and Nuclear Envelope Marker, PDSS1, PDSS2, PDZ-RhoGEF, PE, Peroxin 1, Peroxin 11α, Peroxin 11β, Peroxin 12, Peroxin 2, Peroxin 3, Peroxin 7, Pex7p, PGAP1, PHM27, PHYHD1, PHYHIPL, plasmolipin, Plb3, Pmp24, Pmp34, PNPLA1, PON3, PPase, PRPK, Rab 18, Rab 19, RAb 19B, Rab 24, Rab 9A, Rab GTPase (RAB; RAS oncogene), Rab40B, Raftlin-2, Ral BP-1, RAP, Rap 1A, Ras2, Reelin, REP-2, RGL3, Rho J, SDPR, SEC14L1, SEC14L2, SEC14L4, SEC14L5, Sec24C, SERINC1, SgK223, SH3TC2, Shank2, Siglec-1, SLC37A3, SOAT2, SPFH1, SSEA-4, ST7, StARD6, Ste18, TBC1D2B, TC 21, TERE1, TM7SF2, TMEM106B, TMEM177, TMEM31, Toxoplasma gondii, TSG-6, TYSND1, UGT2B, VAP-B/C, VSV-G, VWA5B1, XKR4, ZC3H7A, ZDHHC, ZDHHC12, ZDHHC21, ZDHHC7, and ZFP169.Activator of:
α1b Tubulin, 3β-hsd1, 3β-HSD2, AADACL1, ABO Blood Group Antigens, ACAT-1, APLP1, apoA-I, APP, ARH, ARHGAP39, ARHGEF37, ARL13A, ARL15, BBS2, BBS5, C14orf109, C20orf95, C8orf80, CD1C, CD63, CD68, Cdc50C, Cdc6, CDKN2AIP, CDS2, Ces1a, CH25H, cHMGCS, COQ5, cyclin 3a, CYP27A1, Cyp2c38, Cyp2c40, CYP46, dachsous, DHCR24, Diversin, DPM1, E2F-8, EBP, EDG-3, Egr-2, ELOVL1, FBL6, FBL7, FDPS, Flotillin-1, Flotillin-2, FRMD6, FTα, Gap 1, GGPS1, GGTase-Iα, GGTase-Iβ, GGTase-IIβ, GTPBP5, GTPBP6, GUP1, HHAT, IDI2, INSIG-2, Integrin αD, KIAA1244, KIAA1822L, Lamin B1, LARGE, LCAT, Lewis Blood Group Antigen, LIN-15A, LIPI, Lmf1, LOC553158, LOC642574, LOC643008, LOC643862, LOC730005, LPAAT-η, LPPR3, LRP1, Ly-GDI, LYPLA1, MLN64, MNS Blood Group Antigens, NMT1, NPC1, NSDHL, ORP-5, PAFAH1B3, PAP-2d, PC-PLD4, PEN-2, Periostin, Pex5p, PGAP1, PIG-O, PIG-Q, PIG-W, PLTP, PMVK, PPOX, PPT2, PTAR1, Rab 30, Rab L3, Ral GDS, Raly, RASA4B, RASGEF1B, RasGRP2, RASSF7, Rho D, Rho F, Rho GAP p190, Rho GAP p190-B, Rho V, Rhotekin, Ribosomal Protein L29, SCARA5, SCP2D1, SEC14L3, SKI-1, SPTSSA, Squalene epoxidase, Squalene synthetase, SR-B1, SREC, StARD10, Supervillin, Synaptotagmin IV, Talin-1, Tiam2, TM7SF3, Trak1, VgI-4, XG FTase, XYLB, and Yap1.Substrate of:
CYP, and Mdr-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lovastatin, 5 mg | sc-200850 | 5 mg | $28.00 | |||
Lovastatin, 25 mg | sc-200850A | 25 mg | $88.00 | |||
Lovastatin, 100 mg | sc-200850B | 100 mg | $332.00 |